mucosolvan沐舒坦品牌怎么样申请店铺

我要投票

mucosolvan沐舒坦在医疗器械行业中的票数：205 更新时间：2025-02-24

mucosolvan沐舒坦是哪个国家的品牌？「mucosolvan沐舒坦」是上海勃林格殷格翰药业有限公司旗下著名品牌。该品牌发源于德国，在1885年期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力mucosolvan沐舒坦品牌出海！通过在本页面挂载mucosolvan沐舒坦品牌的产品链接和联系邮箱，可以提高mucosolvan沐舒坦产品曝光！跨境电商爆单神器，目前只要100元/年哦~

咳嗽药十大品牌，1885年创于德国，以生产酒石酸，乳酸等化工产品起家，致力于研发、生产和营销药品的创新企业

勃林格殷格翰是上较大、成功的私人拥有的制药集团。自1885年成立至今，家族拥有的勃林格殷格翰一直专注于研发、生产和营销创新的药品。主要业务包括处方药，消费自主保健药品，生物制药及动物保健。经过百年的发展，勃林格殷格翰的足迹从德国莱茵河畔延伸向全球40多个国家和地区。

在全球

1885年，阿尔伯特.勃林格先生在德国法兰克福附近的殷格翰城创立了勃林格殷格翰公司。

一百多年来，研究与开发驱动着公司的发展。从最初生产酒石酸，乳酸等化工产品开始，到今天许多广为人知药品的推出，勃林格殷格翰公司在研发上的巨额投入使其在呼吸、心血管、中枢神经、肠胃道等领域拥有优秀的产品，从而赢得有利的市场地位。至今公司已在德国、意大利、奥地利、美国、加拿大、阿根廷和日本设立7个研发中心并投入巨资用于新产品的研究与开发。

在中国

1994年3月勃林格殷格翰以办事处的形式进入中国，揭开了在中国的发展篇章。1995年5月，勃林格殷格翰国际贸易（上海）有限公司注册成立。1998年初进驻上海张江“药谷”成立上海勃林格殷格翰药业有限公司，投资额达2900万美元，标志着勃林格扎根中国的决心。位于张江的现代化工厂，引进了专业的制药设备，设计和管理标准可以和任何其它国家的勃林格殷格翰工厂媲美。工厂严格按照国际GMP标准生产。

勃林格殷格翰在中国的主要业务包括处方药，消费者自主保健药品及动物保健。业务范围遍及全国各主要省市和地区。公司不断把其优秀的产品带来中国市场，上市的产品覆盖呼吸、心血管、中枢神经、抗爱滋病等重要领域，并在业界和市场获得了广泛的美誉和认可。

保健业务

随着人们自我保健意识的提高，用于维持和改善健康、预防疾病，及治疗一些轻微疾病如感冒咳嗽等的消费者自主保健药品正越来越显示其重要性。勃林格殷格翰自主保健药品部专注于非处方药和保健食品的研制生产和销售。旗下产品线主要涵盖身心健康，感冒咳嗽，解热镇痛及血管保健等四个品类。

作为勃林格殷格翰公司的核心业务之一，专注于为中国的消费者提供高品质的自主保健药品。沐舒坦® 片剂和口服溶液均已进入非处方药目录。它能有效调节气道的浆液和粘液分泌，活化纤毛粘液运输系统，能发挥表面活性物质的正常保护功能，因而廓清效果深入肺泡。沐舒坦疗效显著，深受广大患者欢迎，而口服溶液更因可口的水果口味得到儿童和家长的喜欢。

The top ten brands of cough medicine, founded in 1885 in Germany, started with the production of tartaric acid, lactic acid and other chemical products, and the innovative enterprise, bringer Ingelheim, devoted to the research, development, production and marketing of drugs, is a large and successful privately owned pharmaceutical group. Since its establishment in 1885, the family owned Boehringer Ingelheim has been focusing on the research and development, production and marketing of innovative drugs. Its main businesses include prescription drugs, consumer self health care drugs, biopharmaceuticals and animal health care. After a hundred years of development, Boehringer Ingelheim's footprint extends from the Rhine River in Germany to more than 40 countries and regions around the world. In 1885, Albert bringer founded the company in the city of Ingelheim near Frankfurt, Germany. For more than 100 years, research and development has driven the development of the company. From the initial production of tartaric acid, lactic acid and other chemical products to the launch of many well-known drugs today, the company's huge investment in research and development makes it have excellent products in the fields of respiration, cardiovascular, central nervous system, gastrointestinal tract and other fields, so as to win a profitable market position. So far, the company has set up 7 R & D centers in Germany, Italy, Austria, the United States, Canada, Argentina and Japan and invested heavily in the research and development of new products. In March 1994, Brigitte Ingelheim entered China in the form of an office, opening a chapter of development in China. In May 1995, bringer Ingelheim international trade (Shanghai) Co., Ltd. was registered and established. At the beginning of 1998, Shanghai bolingeringelheim Pharmaceutical Co., Ltd. was established in Zhangjiang "pharmaceutical Valley" in Shanghai, with an investment of 29 million US dollars, marking Bolinger's determination to take root in China. The modern chemical plant in Zhangjiang has introduced professional pharmaceutical equipment, and its design and management standards are comparable to those of any other breingelheim plant. The factory strictly follows the international GMP standard production. The main business of Boehringer Ingelheim in China includes prescription drugs, consumer independent health care drugs and animal health care. The business scope covers all major provinces, cities and regions of the country. The company continues to bring its excellent products to the Chinese market. The products on the market cover breathing, cardiovascular, central nervous system, anti AIDS and other important fields, and have gained a wide reputation and recognition in the industry and market. With the improvement of people's self-awareness of health care, the importance of consumer independent health care drugs used to maintain and improve health, prevent diseases, and treat some minor diseases such as cold and cough is becoming more and more obvious. Boehringer Ingelheim's independent health medicine department focuses on the development, production and sales of over-the-counter drugs and health food. Its product line mainly covers four categories: physical and mental health, cold and cough, antipyretic and analgesic, and vascular health care. As one of the core businesses of Boehringer Ingelheim, it focuses on providing high-quality independent health care drugs for Chinese consumers. Both ambroxol ® tablets and oral solutions have entered the OTC list. It can effectively regulate the secretion of serous and mucus in the airway, activate the ciliated mucus transport system, and play the normal protective function of surfactant, so the clearance effect goes deep into the alveoli. Ambroxol is very effective and popular among patients, while oral solution is popular among children and parents for its delicious fruit taste.

本文链接： https://brand.waitui.com/e15ab3121.html 联系电话：请联系客服添加